Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Low-Carbohydrate Diabetes Prevention Program

11 décembre 2018 mis à jour par: Dina Griauzde, Internal Medicine, University of Michigan

A Mixed Methods Pilot Study of a Low-Carbohydrate Diabetes Prevention Program Among Individuals With Prediabetes

The investigators will conduct a single-arm mixed methods pilot study to estimate weight loss as well as the percentage of participants who achieve 5% weight loss in a 16-week, Low-Carbohydrate Diabetes Prevention Program (LC-DPP). Weight loss from the pilot LC-DPP cohort will be compared to weight loss outcomes from previously published DPP studies. The investigators will also evaluate secondary outcomes including change in physical activity, mental health, psychosocial functioning, and hemoglobin A1c over the 6-month study period.

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

An estimated 86 million US adults are have prediabetes, and, without intervention, many will develop T2DM over time. Fortunately, T2DM can be prevented or delayed through modest lifestyle changes. The landmark Diabetes Prevention Program (DPP) Trial demonstrated a 58 percent reduction in the 3-year incidence of T2DM among individuals with prediabetes who achieved 7 percent body weight loss and engaged in routine physical activity. Accordingly, the DPP lifestyle intervention has been translated to communities across the United States, and, on average, participant weight change is 4 percent at 12 months. Thus, while group-based DPPs and can effectively promote weight loss among some participants, many DPP participants do not achieve the program goal of 5 to 7 percent body weight loss.

Novel strategies to help participants achieve DPP weight-loss goals are important for two key reasons. First, weight loss is the primary driver of T2DM risk reduction, and the potential population health impact of the intervention is diminished when participants do not lose weight. Second, a growing number of health plans including Medicare offer coverage for the DPP and proposed reimbursement is largely tied to weight loss of at least 5 percent at 6 months and 12 months. The DPP costs approximately $400-$500 per participant per year. Unfortunately, organizations that offer the DPP may be reimbursed for much less than this if participants do not meet weight loss goals, which could significantly compromise the program's long-term financial sustainability.

One promising approach to help DPP participants lose more weight may be through a low-carbohydrate (LC) dietary intervention. Consistent with United States Dietary Guidelines (USDG), the original DPP Trial and translational group-based curricula recommend a low-fat (LF), calorie-restricted diet. However, there is growing controversy regarding the scientific merit of the Dietary Guidelines as well as growing recognition that LC diets may be more effective than LF diets for short-term weight loss and long-term weight maintenance. Notably, weight loss occurs without calorie restriction and LC diets improve blood glucose levels among individuals with T2DM and insulin resistance. Thus, a LC dietary intervention for prediabetes may augment individual weight loss and T2DM risk reduction while also maximizing third-party reimbursement.

The aim of this mixed methods pilot study is to test whether a LC-DPP may lead to greater weight loss than the original DPP. In addition to objective measures of this program's preliminary efficacy (e.g. weight, HbA1c) the study team will also obtain qualitative participant feedback on the intervention. Taken together, these data will be used to improve the curriculum and inform a larger-scale intervention.

Type d'étude

Interventionnel

Inscription (Réel)

22

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • Michigan Medicine

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion criteria:

  1. Overweight, defined as BMI≥25 kg/m2 [31]
  2. HbA1c between 5.7-6.4% drawn within 6 months of the study start date
  3. Willingness to participate in group-based classes
  4. Able to engage in at least light physical activities such as walking.

Exclusion criteria:

  1. History of type 1 diabetes or type 2 diabetes
  2. Current participation in another lifestyle or behavior change program or research study
  3. Vegetarian or vegan lifestyle
  4. History of bariatric surgery
  5. Inability to read, write, or speak English
  6. Inability to provide informed consent
  7. Women who are pregnant or intend to become pregnant during the intervention period.
  8. Insured by Premier Care or Grad Care; these individuals have the opportunity to participate in a standard DPP, which is offered as a covered benefit through their health plan.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Low-Carbohydrate Diabetes Prevention Program
At least 20 individuals with prediabetes will participate in a year-long , group-based program.
LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in body weight per participant over the study period
Délai: Baseline, 12 months
Measured as percent body weight loss per participant
Baseline, 12 months
Percentage of participants who achieve weight loss goal
Délai: Baseline,12 months
Measured as percentange of participants who achieve 5% total body weight loss
Baseline,12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in self-reported weekly physical activity minutes
Délai: Baseline, 12 months
Participants will maintain a log of weekly physical activity minutes
Baseline, 12 months
Change in physical activity measured using the International Physical Activity Questionnaire
Délai: Baseline, 12 months
Participants will complete this validated survey
Baseline, 12 months
Change in food cravings measured using the Control of Eating Questionnaire
Délai: Baseline, 12 months
Participants will complete this validated survey
Baseline, 12 months
Change in stress eating measured using the Palatable Eating Motives Scale
Délai: Baseline, 12 months
Participants will complete this validated survey
Baseline, 12 months
Change in self-reported health measured using the Global Health PROMIS Questionnaire
Délai: Baseline, 12 months
Participants will complete this validated survey
Baseline, 12 months
Change in autonomous motivation measured using the Treatment Self-Regulation Questionnaire
Délai: Baseline, 12 months
Participants will complete this validated survey
Baseline, 12 months
Change in hemoglobin A1c
Délai: Baseline, 12 months
Measured using a laboratory blood draw
Baseline, 12 months
Session attendance
Délai: Baseline, 12 months
Measured as the number of sessions attended per participant
Baseline, 12 months
Study attrition
Délai: Baseline, 12 months
Number of participants lost to follow-up
Baseline, 12 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change in diet as assessed by qualitative review of foods logs
Délai: Baseline, 12 months
Participants will maintain weekly food logs
Baseline, 12 months
Change in diet as assessed by response to survey questions
Délai: Baseline, 12 months
Participants will respond to exploratory survey questions about diet created by the study team.
Baseline, 12 months
Change in physical symptoms
Délai: Baseline, 12 months
Participants will respond to exploratory survey questions about physical symptoms created by the study team.
Baseline, 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

11 septembre 2017

Achèvement primaire (Réel)

7 novembre 2018

Achèvement de l'étude (Réel)

7 novembre 2018

Dates d'inscription aux études

Première soumission

15 août 2017

Première soumission répondant aux critères de contrôle qualité

22 août 2017

Première publication (Réel)

23 août 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 décembre 2018

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 décembre 2018

Dernière vérification

1 décembre 2018

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner